Advanced IRB

Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit

Retrieved on: 
Tuesday, October 26, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Fibrosis, Melanoma, Human, Cancer, Technology, HCC, Industry, Prostate, Institute of Liver and Biliary Sciences, Drug development, Writing, TASE, Regeneration, CANF, Patient, Psoriasis, Liver cancer, NYSE, Food, Erectile dysfunction, U.S. Securities and Exchange Commission, SEC, Hepatocellular carcinoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Advanced IRB, Forward-looking statement, Company, Clinical trial, COVID-19, Fatty liver disease, NASH, Risk, Liver, Colon, Pharmaceutical industry

The presentation titled Driving Innovation to Shape Future Pipelines: Latest Updates on Namodenoson Clinical Trial Data focuses on exploring study design for optimizing clinical outcomes, strategies for overcoming the translational gap through a holistic approach to analyzing clinical development, and understanding clinical trial data and future implications.

Key Points: 
  • The presentation titled Driving Innovation to Shape Future Pipelines: Latest Updates on Namodenoson Clinical Trial Data focuses on exploring study design for optimizing clinical outcomes, strategies for overcoming the translational gap through a holistic approach to analyzing clinical development, and understanding clinical trial data and future implications.
  • The 5th Annual Antifibrotic Drug Development Summit will be held on November 1 3, 2021.
  • Dr. Fishman will present on Wednesday, November 3 at 3:45 pm ET.
  • The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19.

Celerion Transforms the Consent Experience for Sites and Patients with Veeva eConsent

Retrieved on: 
Wednesday, October 6, 2021
Result, Compliance, Stacy (given name), Patient, Risk, Comprehension, Investor, Conversation, ICF, SEC, Financial condition report, Professional corporation, Program, Analysis, COVID-19, NYSE, Industry, Advanced IRB, Management, Pharmaceutical industry

PLEASANTON, Calif., Oct. 6, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Celerion adopted Veeva eConsent , a MyVeeva for Patients solution,to complete electronic consent for its Phase I clinical trials.

Key Points: 
  • PLEASANTON, Calif., Oct. 6, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Celerion adopted Veeva eConsent , a MyVeeva for Patients solution,to complete electronic consent for its Phase I clinical trials.
  • With Veeva eConsent, Celerion is shifting from manual and paper-based informed consent to a completely digital process.
  • A global leader in early clinical research services, Celerion uses Veeva SiteVault to digitally author, manage, and distribute informed consent forms (ICF).
  • "Veeva eConsent improves the informed consent process for all parties involved by delivering an intuitive and digital experience for patients and easy collaboration with sites and IRBs for sponsors."

Celerion Transforms the Consent Experience for Sites and Patients with Veeva eConsent

Retrieved on: 
Wednesday, October 6, 2021
Result, Review, Compliance, Efficiency, Stacy (given name), Patient, Risk, Comprehension, Investor, Conversation, ICF, Financial condition report, Industry, Professional corporation, Program, Analysis, COVID-19, NYSE, SEC, Advanced IRB, Pharmaceutical industry

BARCELONA, Spain, Oct. 6, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Celerion adopted Veeva eConsent, a MyVeeva for Patients solution, to complete electronic consent for its Phase I clinical trials. With Veeva eConsent, Celerion is shifting from manual and paper-based informed consent to a completely digital process. The company is using Veeva eConsent across multiple studies and has consented more than 200 subjects. 

Key Points: 
  • With Veeva eConsent, Celerion is shifting from manual and paper-based informed consent to a completely digital process.
  • "Veeva eConsent gives us an easy-to-use solution that can keep up with our fast-paced environment and improve participant comprehension of study procedures.
  • A global leader in early clinical research services, Celerion uses Veeva SiteVault to digitally author, manage, and distribute informed consent forms (ICF).
  • "Veeva eConsent improves the informed consent process for all parties involved by delivering an intuitive and digital experience for patients and easy collaboration with sites and IRBs for sponsors."

Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update

Retrieved on: 
Thursday, August 26, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Company, Commercialization, U.S. FDA, COVID-19, Cirrhosis, Enrollment, CANF, Institute of Liver and Biliary Sciences, Cancer, Rheumatoid arthritis, SSC, Liver cancer, Survival, Treatment, Phase, HCC, Research, Corporation, Janet Woodcock, Patent, Animal, Advanced IRB, Cat, NYSE, Psoriasis, Institutional review board, CBD, Development, Ministry, Osteoarthritis, Use, Patient, Dog, NASH, Commencement at Central Connecticut State University, Exercise, TASE, Pharmaceutical industry, Health insurance, Medical device, Cryptocurrency

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June 30, 2021.

Key Points: 
  • (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June 30, 2021.
  • Patient enrollment is expected to commence Q3 2021, ahead of the prior expected start date of Q4 2021.
  • Financial income, net for the six months ended June 30, 2021 was $0.20 million compared to financial expense, net of $0.12 million for the same period in 2020.
  • The Company's consolidated financial results for the six months ended June 30, 2021 are presented in accordance with US GAAP Reporting Standards.